Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Short Interest Down 99.6% in March

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 100 shares, a decline of 99.6% from the February 29th total of 24,800 shares. Based on an average daily volume of 10,800 shares, the days-to-cover ratio is presently 0.0 days.

Inhibitor Therapeutics Stock Performance

Shares of INTI stock remained flat at $0.07 during mid-day trading on Friday. The company’s stock had a trading volume of 100,000 shares, compared to its average volume of 7,350. Inhibitor Therapeutics has a 12 month low of $0.01 and a 12 month high of $0.30. The firm’s 50-day moving average price is $0.08 and its two-hundred day moving average price is $0.08.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.